Logo image of STXS

STEREOTAXIS INC (STXS) Stock Price, Forecast & Analysis

USA - NYSE Arca - NYSEARCA:STXS - US85916J4094 - Common Stock

2.46 USD
+0.03 (+1.23%)
Last: 12/26/2025, 8:17:19 PM
2.47 USD
+0.01 (+0.41%)
After Hours: 12/26/2025, 8:17:19 PM

STXS Key Statistics, Chart & Performance

Key Statistics
Market Cap229.57M
Revenue(TTM)26.92M
Net Income(TTM)-24.64M
Shares93.32M
Float63.60M
52 Week High3.59
52 Week Low1.54
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.28
PEN/A
Fwd PEN/A
Earnings (Next)03-02 2026-03-02/amc
IPO2004-08-12
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


STXS short term performance overview.The bars show the price performance of STXS in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 -10 -15

STXS long term performance overview.The bars show the price performance of STXS in the last 1, 2 and 3 years. 1 year 2 years 3 years 10 20 30 40

The current stock price of STXS is 2.46 USD. In the past month the price increased by 1.23%. In the past year, price increased by 7.42%.

STEREOTAXIS INC / STXS Daily stock chart

STXS Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.02 217.08B
ISRG INTUITIVE SURGICAL INC 67.11 204.83B
BSX BOSTON SCIENTIFIC CORP 32.56 142.40B
SYK STRYKER CORP 26.9 135.46B
BDX BECTON DICKINSON AND CO 13.62 56.04B
IDXX IDEXX LABORATORIES INC 54.6 54.98B
EW EDWARDS LIFESCIENCES CORP 33.79 50.40B
GEHC GE HEALTHCARE TECHNOLOGY 18.22 38.09B
RMD RESMED INC 24.72 35.73B
DXCM DEXCOM INC 36.33 26.35B
PODD INSULET CORP 63.16 20.31B
ZBH ZIMMER BIOMET HOLDINGS INC 11.22 17.99B

About STXS

Company Profile

STXS logo image Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 139 full-time employees. The company went IPO on 2004-08-12. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

Company Info

STEREOTAXIS INC

710 N Tucker Blvd, Ste 110

St. Louis MISSOURI 63108 US

CEO: David L. Fischel

Employees: 139

STXS Company Website

STXS Investor Relations

Phone: 13146786100

STEREOTAXIS INC / STXS FAQ

What does STEREOTAXIS INC do?

Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 139 full-time employees. The company went IPO on 2004-08-12. Its proprietary robotic technology, Robotic Magnetic Navigation (RMN), fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Company’s primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.


What is the current price of STXS stock?

The current stock price of STXS is 2.46 USD. The price increased by 1.23% in the last trading session.


Does STXS stock pay dividends?

STXS does not pay a dividend.


What is the ChartMill rating of STEREOTAXIS INC stock?

STXS has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


On which exchange is STXS stock listed?

STXS stock is listed on the NYSE Arca exchange.


Can you provide the PE ratio for STXS stock?

STEREOTAXIS INC (STXS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.28).


What is the Short Interest ratio of STEREOTAXIS INC (STXS) stock?

The outstanding short interest for STEREOTAXIS INC (STXS) is 4.74% of its float.


STXS Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to STXS. When comparing the yearly performance of all stocks, STXS is a bad performer in the overall market: 70.77% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

STXS Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to STXS. While STXS seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

STXS Financial Highlights

Over the last trailing twelve months STXS reported a non-GAAP Earnings per Share(EPS) of -0.28.


Industry RankSector Rank
PM (TTM) N/A
ROA -59.84%
ROE -364.9%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%12.5%
Sales Q2Q%-18.83%
EPS 1Y (TTM)0%
Revenue 1Y (TTM)0.55%

STXS Forecast & Estimates

10 analysts have analysed STXS and the average price target is 4.28 USD. This implies a price increase of 74.15% is expected in the next year compared to the current price of 2.46.

For the next year, analysts expect an EPS growth of 13.03% and a revenue growth 20.4% for STXS


Analysts
Analysts82
Price Target4.28 (73.98%)
EPS Next Y13.03%
Revenue Next Year20.4%

STXS Ownership

Ownership
Inst Owners46.53%
Ins Owners19.06%
Short Float %4.74%
Short Ratio5.28